• Profile

Risk stratification for prostate cancer management: value of the Cambridge prognostic group classification for assessing treatment allocation

BMC Medicine Jun 01, 2020

Parry MG, Cowling TE, Sujenthiran A, et al. - This study was attempted to assess radical treatment rates according to Cambridge Prognostic Group (CPG) in men diagnosed with non-metastatic prostate cancer in England between 2014 and 2017. Researchers distinguished patients diagnosed with non-metastatic prostate cancer from the National Prostate Cancer Audit database. They calculated risk ratios (RR) for undergoing radical treatment according to CPG and for receiving radiotherapy for those treated radically. They applied funnel plots to show variation in radical treatment rates across hospitals. The study population consisted of 61,999 men with 10,963 (17.7%) in CPG1 (lowest risk group), 13,588 (21.9%) in CPG2, 9452 (15.2%) in CPG3, 12,831 (20.7%) in CPG4, and 15,165 (24.5%) in CPG5 (highest risk group). Men were classified in five risk groups by CPG classification that are about equal in size. it shows variations in treatment practices in men with intermediate-risk disease (CPG2 and CPG3) and in men with high-risk disease (CPG4 and CPGP5) that are not visible when applying the traditional three-tiered risk classification.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen